Aaron Brice, MD
Interventional Cardiology · New Britain, CTNPI 1700204872
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 175 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for interventional cardiology clinicians in CT, where the typical reported total is $5,446.
Across 175 payments — averaging $33.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$893
- Boston Scientific$745
- Novartis$534
- Medtronic$380
- Pfizer$334
- E.r. Squibb & Sons, L.L.C.$308
- plus $3K from 24 others
What the payments were for
- Food & beverage$5,872100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 11 | $893 |
| Boston Scientific | 18 | $745 |
| Novartis | 28 | $534 |
| Medtronic(2 entities) | 5 | $380 |
| Pfizer | 18 | $334 |
| E.r. Squibb & Sons, L.L.C. | 18 | $308 |
| Amgen | 11 | $291 |
| Philips North America LLC | 2 | $266 |
| Abiomed | 5 | $262 |
| Livanova USA, Inc. | 2 | $199 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $195 |
| Biotronik Inc. | 4 | $192 |
| Alnylam Pharmaceuticals Inc. | 2 | $143 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $135 |
| Cardiovascular Systems Inc. | 1 | $124 |
| Johnson & Johnson | 6 | $117 |
| Kiniksa Pharmaceuticals, Ltd. | 5 | $113 |
| AstraZeneca | 4 | $102 |
| Shockwave Medical, Inc | 1 | $70 |
| Lexicon Pharmaceuticals, Inc. | 3 | $67 |
| Novo Nordisk | 3 | $62 |
| Merck | 3 | $60 |
| Regeneron Healthcare Solutions, Inc. | 2 | $56 |
| Boehringer Ingelheim | 2 | $43 |
| Bayer | 2 | $41 |
| Esperion Therapeutics, Inc. | 2 | $38 |
| Heartflow, Inc. | 2 | $33 |
| Scpharmaceuticals Inc. | 2 | $30 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELUVIA$247
- LifeSPARC$157
- MitraClip System$150
- (8977) Zenition 70$148
- Orsiro Mission$140
- PK Papyrus$140
- PERCLOSE PROGLIDE$125
- Diamondback Coronary$124
- AMVUTTRA$122
- Merlin Connectivity and Remote$121
- US Und$118
- LifeVest$112
- Perclose ProGlide suture mediated closure system$112
- Absolute Pro vascular stent system$110
- Resolute$109
- Impella$108
How this compares
$5,872 in reported general payments places this provider in the 50th percentile of 73 interventional cardiology providers in Connecticut.
See all interventional cardiology providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 211 | $204,705 |
| EntrestoSacubitril/Valsartan | 48 | $60,890 |
| XareltoRivaroxaban | 25 | $33,741 |
| Repatha SureclickEvolocumab | 44 | $33,324 |
| BrilintaTicagrelor | 26 | $23,415 |
| Metoprolol Succinate | 211 | $2,115 |
| Rosuvastatin Calcium | 176 | $1,585 |
| Atorvastatin Calcium | 200 | $1,546 |
| Ezetimibe | 67 | $1,076 |
| Carvedilol | 112 | $950 |
| FenofibrateFenofibrate Nanocrystallized | 23 | $859 |
| Flecainide Acetate | 11 | $784 |
| Torsemide | 44 | $744 |
| Nifedipine ErNifedipine | 43 | $661 |
| Amlodipine Besylate | 93 | $648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $334 | $204,705211 claims |
| NovartisEntresto | $534 | $60,89048 claims |
| Johnson & JohnsonXarelto | $117 | $33,74125 claims |
| AstraZenecaBrilinta | $102 | $23,41526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 73 interventional cardiology providers in Connecticut.
Other interventional cardiology in New Britain
- Wael ElmallahNew Britain$9K
- Robert BorkowskiNew Britain$8K
- Manny KatsetosNew Britain$7K
- Amit VoraNew Haven$409K
- Craig ThompsonHartford$222K
- Michael NannaNew Haven$60K
- Jawad HaiderBloomfield$44K
- Sameer NagpalNew Haven$43K
- Khagendra DahalFarmington$42K
- Abdul QaziHartford$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.